User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

Interactions with Platform & by Email *

INTERACTIONS

Unique # Participated *

PARTICIPANTS

Responses Validated *

VALIDATIONS

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Outlook.....II-1
Global Market Analysis.....II-1
Plummeting Growth for Statins.....II-1
1$100
   Non-Statin Drug Segment to Drive Future Growth.....II-2
Major Drugs Face Patent Expiry.....II-2
Major Dyslipidemia Drugs & Patent Expiry.....II-2
1$100
   Key Challenges Faced by Dyslipidemia Market.....II-3
Patents Expiry.....II-3
Generic Penetration.....II-3
Table 1: Increasing Penetration of Generics in the US and European Dyslipidemia Therapeutics Market by Volume (2005-2009) (includes corresponding Graph/Chart).....II-3
Strict FDA Regulations.....II-3
Pipeline Drugs: Focused on Unmet Needs.....II-3
1$350
   List of Select Pipeline Drugs for Treatment of Dyslipidemia (2009).....II-41$100
   Novel Combination Products and Future Therapies to Change Landscape.....II-5
Fixed-Dose Combination Therapies.....II-5
Simcor - The Foremost Fixed-Dose Combination.....II-5
CERTRIAD.....II-5
Combination Therapy – Treatment for Diabetic Dyslipidemia.....II-5
1$100
   Market Competition and Brand Dynamics.....II-6
Lipitor – Top Selling Statin.....II-6
Table 2: Lipitor Sales Worldwide (2004-2008) (In US$ Billion) (includes corresponding Graph/Chart).....II-6
1$350
   Crestor – The Rising Statin.....II-7
Table 3: Crestor Sales Worldwide (2004-2008) (In US$ Billion) (includes corresponding Graph/Chart).....II-7
Vytorin (Ezetimibe/Simvastatin).....II-7
1$350
   Lovaza – The Leading Non-Statin.....II-8
Trilipix –The Foremost Combination Therapy Drug.....II-8
Table 4: Leading Non-Statin Brands in the US and Europe (2009): Percentage Breakdown of Value Sales for Tricor, Niaspan, Lovaza, Antara, Triplix and Others (includes corresponding Graph/Chart).....II-8
1$350
   Introduction to Dyslipidemia.....II-9
Classification.....II-9
Causes.....II-9
1$100
   Hereditary Dyslipidemia.....II-10
Types.....II-10
Familial Combined hyperlipidemia.....II-10
Familial Hypertriglyceridemia.....II-10
Familial Dysbetalipoproteinemia.....II-10
Hypoalphalipoproteinemia.....II-10
Symptoms of Dyslipidemia.....II-10
Co-morbid Disorders and Risk Factors.....II-10
1$100
   Diagnosis.....II-11
Treatment Strategies.....II-11
Drug Therapy.....II-11
1$100
   Classes of Antidyslipidemic Drugs.....II-12
Statins.....II-12
Types of Statins.....II-12
Various Types of Statins Along With Their Brand Names and Availability in Market as
  Prescription Generic Drugs.....II-12
1$100
   Growth Drivers for Statins.....II-13
Impediments to Growth.....II-13
Non-Statins.....II-13
Types of Non-Statins.....II-13
Fibric Acid Derivatives.....II-13
Bile Acid Sequestrants.....II-13
1$100
   Cholesterol Absorption Inhibitors.....II-14
Potential Growth Drivers for Non-Statins.....II-14
Market Opportunities.....II-14
Non-Statin Products in Pipeline.....II-14
Select Non -Statin Drugs in Pipeline (2009).....II-14
1$100
   Lipoprotein Synthesis Inhibitor.....II-15
Fat Supplements.....II-15
1$100
   Kowa Pharmaceuticals America Receives FDA Approval for Livalo.....II-16
Aegerion Pharmaceuticals Releases Final Data for Lomitapide (AEGR-733) Phase II
  Trials.....II-16
Dr Reddy's Laboratories Obtains Approval for Two Drugs.....II-16
1$100
   Arena Pharmaceuticals Commences Phase II Clinical Trial for Niacin Receptor
  Agonist.....II-17
Abbott Laboratories and Solvay Pharmaceuticals Receives FDA Approval for
  Trilipix.....II-17
AstraZeneca and Abbott Submit NDA for CERTRIAD™.....II-17
1$100
   Amarin Secures FDA Approval for AMR101 Phase III Trials.....II-18
Abbott's Receives Approval for using TRILIPIX® as a Combination Therapy.....II-18
Takeda Commences Phase III Trial for ATL-962.....II-18
AAIPharma Licenses ProCR Oral Drug Delivery Technology to Cortria.....II-18
1$100
   Essentialis Finishes Patient Enrolment Process.....II-19
Metabolex Releases Results from Phase II Clinical Trial for MBX-8025.....II-19
Karo Bio Releases Phase II Study Results for Eprotirome.....II-19
1$100
   Merck Sharp & Dohme Receives Approval for Tredaptive.....II-20
Merck Obtains Patent Approval for Two Drugs.....II-20
Resverlogix Completes Phase 1a Trials for RVX-208.....II-20
Abbott Obtains Approval from FDA for Simcor.....II-20
Surface Logix Releases Results of Phase 2a Clinical Trial for SLx-4090.....II-20
1$100
   Merck’s Cholesterol Pill to Receive FDA Approval in 2013.....II-21
Schering-Plough Obtains Approval for Marketing ZETIA®.....II-21
1$100
   Abbott and Solvay Group Enter into Definitive Agreement.....II-22
Daiichi Sankyo Establishes New Subsidiary.....II-22
AstraZeneca Introduces Crestor.....II-22
1$100
   Kowa Takes Over ProEthic Pharmaceuticals.....II-23
Ore Pharmaceuticals Acquires Exclusive Rights from Roche to Develop Romazarit.....II-23
AstraZeneca Enters into Agreement with Abbott.....II-23
1$100
   Pfizer Sells Esperion Therapeutics.....II-24
Merck Establishes New Biotechnology Division.....II-24
GlaxoSmithKline Acquires Reliant Pharmaceuticals.....II-24
1$100
   Abbott Laboratories (US).....II-25
AstraZeneca, PLC (UK).....II-25
GlaxoSmithKline, Inc. (US).....II-25
1$100
   Merck & Co., Inc. (US).....II-26
Mylan, Inc. (US).....II-26
Novartis AG (Switzerland).....II-26
Pfizer, Inc. (US).....II-26
1$100
   Teva Pharmaceutical Industries Ltd. (Israel).....II-271$100
   Table 5: World Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Geographic Region/ Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-281$350
   Table 6: World 10-Year Perspective for Dyslipidemia Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-291$350
   Table 7: World Recent Past, Current & Future Analysis for Statins by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-301$350
   Table 8: World 10-Year Perspective for Statins by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-311$350
   Table 9: World Recent Past, Current & Future Analysis for Non-Statins by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-321$350
   Table 10: World 10-Year Perspective for Non-Statins by Geographic Region/ Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-331$350
   A. Market Analysis.....III-1
Outlook.....III-1
Demographics.....III-1
Dyslipidemia in Elderly Population.....III-1
1$75
   Market Share Statistics.....III-2
Table 11: The US Market for Antidyslipidemic Drugs (2007): Percentage Share Breakdown of Leading Brands by Prescription - Lipitor, Vytorin, Crestor, Zetia, Tricor and, Generics (includes corresponding Graph/Chart).....III-2
Product Approvals And Clinical Trials.....III-2
5$200
   Strategic Corporate Developments.....III-72$125
   Key Players.....III-93$175
   B. Market Analytics.....III-12
Table 12: US Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment - Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-12
1$200
   Table 13: US 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015 (includes corresponding Graph/Chart).....III-131$200
   A. Market Analysis.....III-14
Strategic Corporate Developments.....III-14
1$75
   B. Market Analytics.....III-15
Table 14: Japanese Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment - Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-15
1$200
   Table 15: Japanese 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015 (includes corresponding Graph/Chart).....III-161$200
   A. Market Analysis.....III-17
Strategic Corporate Developments.....III-17
1$75
   B. Market Analytics.....III-18
Table 16: European Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-18
1$200
   Table 17: European 10-Year Perspective for Dyslipidemia Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, & Rest of Europe Markets for 2006, 2009, and 2015 (includes corresponding Graph/Chart).....III-191$200
   Table 18: European Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment - Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-201$200
   Table 19: European 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015 (includes corresponding Graph/Chart).....III-211$200
   Market Analysis.....III-22
Table 20: French Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment - Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-22
1$200
   Table 21: French 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015 (includes corresponding Graph/Chart).....III-231$200
   Market Analysis.....III-24
Table 22: German Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment - Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-24
1$200
   Table 23: German 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015 (includes corresponding Graph/Chart).....III-251$200
   Market Analysis.....III-26
Table 24: Italian Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment - Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-26
1$200
   Table 25: Italian 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015 (includes corresponding Graph/Chart).....III-271$200
   Market Analysis.....III-28
Table 26: UK Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment - Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-28
1$200
   Table 27: UK 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015 (includes corresponding Graph/Chart).....III-291$200
   Market Analysis.....III-30
Table 28: Spanish Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment - Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-30
1$200
   Table 29: Spanish 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015 (includes corresponding Graph/Chart).....III-311$200
   Market Analysis.....III-32
Table 30: Rest of Europe Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment - Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-32
1$200
   Table 31: Rest of Europe 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015 (includes corresponding Graph/Chart).....III-331$200
   A. Market Analysis.....III-34
China.....III-34
Outlook.....III-34
Key Player.....III-34
1$75
   Strategic Corporate Developments.....III-351$75
   B. Market Analytics.....III-36
Table 32: Rest of World Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment - Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-36
1$200
   Table 33: Rest of World 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015 (includes corresponding Graph/Chart).....III-371$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com